QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
QQQ   311.16 (-0.18%)
AAPL   156.41 (+3.71%)
MSFT   264.07 (-0.20%)
META   192.66 (+2.06%)
GOOGL   106.76 (-0.91%)
AMZN   107.96 (-4.38%)
TSLA   198.28 (+5.32%)
NVDA   216.32 (-0.35%)
NIO   11.70 (-2.17%)
BABA   107.45 (-2.09%)
AMD   88.29 (-0.02%)
T   19.91 (-1.82%)
MU   63.39 (+0.35%)
F   13.18 (-7.96%)
CGC   3.06 (-2.55%)
GE   82.99 (-1.13%)
DIS   112.47 (-0.65%)
AMC   6.63 (+9.05%)
PFE   44.10 (-0.54%)
PYPL   86.75 (-0.24%)
NFLX   369.27 (+0.65%)
NASDAQ:EIGR

Eiger BioPharmaceuticals - EIGR Stock Forecast, Price & News

$2.04
-0.11 (-5.12%)
(As of 02/3/2023 10:46 AM ET)
Add
Compare
Today's Range
$2.04
$2.11
50-Day Range
$1.02
$4.54
52-Week Range
$0.96
$10.02
Volume
78,513 shs
Average Volume
682,740 shs
Market Capitalization
$89.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.33

Eiger BioPharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
148.1% Upside
$5.33 Price Target
Short Interest
Healthy
2.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$71,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.28) to ($1.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

35th out of 1,030 stocks

Biological Products, Except Diagnostic Industry

8th out of 169 stocks

EIGR stock logo

About Eiger BioPharmaceuticals (NASDAQ:EIGR) Stock

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Stock News Headlines

Biotech Stock Alert
Read Small Pharma's depression clinical trial results.
Elon Musk Claims Solar Will Soon Power the World
The world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Eiger BioPharmaceuticals Announces Leadership Change
Eiger BioPharmaceuticals' Debt Overview
See More Headlines
Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Company Calendar

Last Earnings
11/04/2021
Today
2/03/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EIGR
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.33
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+161.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-33,920,000.00
Net Margins
-660.21%
Pretax Margin
-659.90%

Debt

Sales & Book Value

Annual Sales
$12.14 million
Book Value
$2.13 per share

Miscellaneous

Free Float
40,813,000
Market Cap
$89.90 million
Optionable
Not Optionable
Beta
1.93

Key Executives

  • David Apelian
    Chief Executive Officer & Director
  • Sriram Ryali
    Chief Financial Officer
  • Ingrid C. Choong
    Senior Vice President-Clinical Development
  • Christopher Kurtz
    Chief Technical Officer
  • Colin Hislop
    Senior VP-Clinical & Development Operations













EIGR Stock - Frequently Asked Questions

Should I buy or sell Eiger BioPharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings
or view top-rated stocks.

What is Eiger BioPharmaceuticals' stock price forecast for 2023?

1 equities research analysts have issued 1 year target prices for Eiger BioPharmaceuticals' stock. Their EIGR share price forecasts range from $3.00 to $9.00. On average, they expect the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 148.1% from the stock's current price.
View analysts price targets for EIGR
or view top-rated stocks among Wall Street analysts.

How have EIGR shares performed in 2023?

Eiger BioPharmaceuticals' stock was trading at $1.18 at the start of the year. Since then, EIGR stock has increased by 82.2% and is now trading at $2.15.
View the best growth stocks for 2023 here
.

Are investors shorting Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,200,000 shares, a decrease of 21.1% from the December 31st total of 1,520,000 shares. Based on an average daily volume of 905,700 shares, the short-interest ratio is currently 1.3 days.
View Eiger BioPharmaceuticals' Short Interest
.

When is Eiger BioPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our EIGR earnings forecast
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.07. The biotechnology company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $2.54 million. Eiger BioPharmaceuticals had a negative net margin of 660.21% and a negative trailing twelve-month return on equity of 106.48%. During the same quarter last year, the firm earned ($0.52) EPS.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.44%), DAVENPORT & Co LLC (0.53%), Sigma Planning Corp (0.26%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Jeffrey S Glenn, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends
.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $2.15.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals (NASDAQ:EIGR) has a market capitalization of $94.75 million and generates $12.14 million in revenue each year. The biotechnology company earns $-33,920,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The official website for the company is www.eigerbio.com. The biotechnology company can be reached via phone at (650) 272-6138, via email at ichoong@eigerbio.com, or via fax at 650-618-1621.

This page (NASDAQ:EIGR) was last updated on 2/3/2023 by MarketBeat.com Staff